Research Article

The APOE ε4 allele is associated with a reduction in FEV₁/FVC in women: A cross-sectional analysis of the Long Life Family Study

Alexander M. Kulminski1*, Amisha V. Barochia2*, Yury Loika1, Nalini Raghavachari3, Konstantin G. Arbeev1, Mary K. Wojczynski4, Bharat Thyagarajan6, Badri N. Vardarajan6, Kaare Christensen7,8, Anatoliy I. Yashin1, Stewart J. Levine2*

1 Biodemography of Aging Research Unit, Social Sciences Research Institute, Duke University, Durham, NC, United States of America, 2 Laboratory of Asthma and Lung Inflammation, Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, United States of America, 3 National Institute on Aging, Gateway Building, Suite, Bethesda, MD, United States of America, 4 Division of Statistical Genomics, Department of Genetics, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, United States of America, 5 Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States of America, 6 Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, NY, United States of America, 7 The Danish Aging Research Center, University of Southern Denmark, Odense C, Denmark, 8 Department of Clinical Genetics and Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense C, Denmark

* These authors contributed equally to this work.

* Alexander.Kulminski@duke.edu (AMK); levines@nhlbi.nih.gov (SJL)

Abstract

Introduction

Murine studies have shown that apolipoprotein E modulates pulmonary function during development, aging, and allergen-induced airway disease. It is not known whether the polymorphic human APOE gene influences pulmonary function.

Objectives

We assessed whether an association exists between the polymorphic human APOE ε2, ε3, and ε4 alleles and pulmonary function among participants in the Long Life Family Study.

Methods

Data from 4,468 Caucasian subjects who had genotyping performed for the APOE ε2, ε3, and ε4 alleles were analyzed, with and without stratification by sex. Statistical models were fitted considering the effects of the ε2 allele, defined as ε2/2 or ε2/3 genotypes, and the ε4 allele, defined as ε3/4 or ε4/4 genotypes, which were compared to the ε3/3 genotype.

Results

The mean FEV₁/FVC ratio (the forced expiratory volume in one second divided by the forced vital capacity) was lower among women with the ε4 allele as compared to women with the
ε3/ε3 genotype or the ε2 allele. Carriage of the APOE ε4 allele was associated with FEV1/FVC, which implied lower values. Further analysis showed that the association primarily reflected women without lung disease who were older than 70 years. The association was not mediated by lipid levels, smoking status, body mass index, or cardiovascular disease.

Conclusions
This study for the first time identifies that the APOE gene is associated with modified lung physiology in women. This suggests that a link may exist between the APOE ε4 allele, female sex, and a reduction in the FEV1/FVC ratio in older individuals.

Introduction
Apolipoprotein E (APOE) plays an essential role in normal lipid homeostasis by removing triglyceride- and cholesterol-containing lipoprotein particles from plasma by binding to cellular receptors of the LDL receptor (LDLR) family[1–3]. Consistent with this, individuals with familial APOE deficiency have severely disrupted lipid catabolism with type III hyperlipoproteinemia and premature cardiovascular disease[4]. In addition to lipid transport, APOE also has important anti-oxidant and anti-inflammatory properties[5–7].

The APOE protein is primarily synthesized by the liver and circulates in plasma[2, 3]. APOE is also expressed by macrophages, alveolar epithelial cells and pulmonary artery smooth muscle cells in the lung, where it may regulate respiratory health and disease[7–12]. For example, a role for APOE in normal lung development has been suggested as male Apoe-deficient mice have increased airway resistance in early adulthood and more rapid loss of lung recoil with age[13, 14]. This suggested that altered lipid metabolism in the absence of APOE may increase inflammation and oxidative stress with resultant abnormal lung mechanics. APOE may also modulate normal surfactant phospholipid synthesis by type II airway epithelial cells. Apoe-deficient mice have increased alveolar levels of the major surfactant lipid, disaturated phosphatidylcholine, which occurs as a consequence of elevated serum levels of triglycerides and very low-density lipoproteins (VLDL)[15]. Studies in murine models have shown that feeding Apoe-deficient mice a high-fat Western diet causes cholesterol accumulation in the lung with resultant pathogenic changes resembling emphysema, pulmonary fibrosis, pulmonary hypertension, and sarcoidosis[7, 16–21]. APOE also has been shown to have protective roles in murine models of asthma, acute lung injury (ALI), emphysema, and pulmonary hypertension[7, 10, 12, 22–25]. For example, APOE can directly bind and neutralize lipopolysaccharide from the cell walls of gram-negative bacteria, which may be a protective mechanism in ALI[26–29]. APOE can also bind mycobacterial lipid antigens, which are then internalized by antigen-presenting cells, which promotes adaptive immune responses to Mycobacterium tuberculosis[30].

It is not known whether the polymorphic human APOE gene influences pulmonary function. Here, we hypothesized that the common polymorphic APOE alleles, ε2, ε3 and ε4, might be associated with modified lung function among 4,554 participants of the Long Life Family Study (LLFS), which is a family-based cohort study that has the goal of identifying factors related to human longevity. We focused on spirometric measures of lung function, including the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC), and the FEV1/FVC ratio (FEV1 divided by the FVC). These are standardized, universal measurements of air flow in and out of lungs that are routinely used, in both clinical care and research, to

Funding: The Long Life Family Study is funded by U01AG023749, U01AG023744, U01AG049508 and U01AG023712 from the National Institute on Aging, NIH, USA. This work was supported by the National Institute on Aging (grant numbers U01 AG023712, P01 AG043352, RO1 AG047310) and the Division of Intramural Research, NHLBI (1ZIAHL006053-08), NIH, USA. The funding source did not participate in the writing of the manuscript or the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Competing interests: The authors have declared that no competing interests exist.
quantify and monitor obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD), as well as restrictive lung disease, such as pulmonary fibrosis.

**Methods**

**The Long-life family study**

Baseline information from 4,954 U.S. and Danish LLFS participants was collected at four field centers using similar questionnaires and in-home physical examinations between 2006 and 2009 on families showing exceptional familial longevity ranked on the basis of a Family Longevity Selection Score, which is a summary-measure of the survival experience of the oldest living generation of siblings relative to what would be expected based on the life tables of a normal population. Disease information was assessed both retrospectively, from self-reports at baseline, and prospectively through 2015. Other eligibility criteria, as well as the design of the LLFS study have previously been described [31–35]. In brief, the U.S. families eligible for the LLFS study must have at least two living siblings aged 80+ years, two living offspring, and a living spouse of either siblings or offspring. Eligible families were enrolled in LLFS if at least three living members (a proband, at least one sibling, and one of their offspring) were willing to participate. In Denmark, individuals who would be aged 90+ years according the Danish National Register of Person were identified and contacted to further assess the family’s eligibility using criteria parallel to those used in the U.S. [34]. Thus, the LLFS includes long-living individuals (probands and siblings), their offspring, and spouses of probands and offspring.

Local institutional review boards of all participating centers approved the LLFS (University of Southern Denmark S-VF-2003227; Boston University H-25140; Columbia University AAAP4119; University of Pittsburgh IRB0509062 and PRO14050142) and all participants provided informed consent [36].

**Sample collection and processing**

Baseline blood samples were collected from all LLFS participants and processed within 48 to 72 hours to isolate serum, plasma, DNA and cryopreserved lymphocytes. DNA was isolated from white blood cells using the automated Autopure DNA extraction method (Qiagen Inc., Gaithersburg, MD). For the 4% of participants from whom blood could not be obtained, DNA was isolated from buccal samples using Oragene kits (DNA Genotek, Ottawa, ON, Canada). The data presented in this manuscript utilized DNA from both sources. Lipid measurements were made from serum.

**APOE genotyping**

Genotyping of the APOE ε2, ε3, and ε4 alleles for LLFS study participants was performed at the Biomedical Genomics Center at the University of Minnesota [37]. APOE genotyping was based on SNPs rs7412 and rs429358 using the Taqman genotyping platform and concordance among genotypes for both SNPs was 100% based on blinded duplicates. The frequencies of the APOE genotypes in a sample of 4,554 LLFS participants were ε2/ε2 (n = 32, 0.7%); ε2/ε3 (n = 683, 15.0%); ε2/ε4 (n = 86, 1.9%); ε3/ε3 (n = 2959, 65.0%); ε3/ε4 (n = 746, 16.4%); and ε4/ε4 (n = 48, 1.0%). The APOE genotypes were in Hardy-Weinberg equilibrium (p = 0.754), thereby implying that the observed genotype distribution did not deviate from the expected distribution in this population. Given the small number of carriers of the three uncommon genotypes, ε2/ε2, ε2/ε4, and ε4/ε4 (3.6% of the LLFS participants), we selected three groups for analysis. The ε2 allele was defined as ε2/ε2 or ε2/ε3 genotypes, the ε4 allele was defined as ε3/ε4 or ε4/ε4 genotypes, and the ε3/ε3 genotype was designated as the reference group for...
the association analyses using regression models (see Analysis section). Statistical models were fitted considering the effect of the ε2 and ε4 alleles as compared to the common ε3/ε3 reference genotype. We prospectively determined that participants with the ε2/ε4 genotype would not be included in the models to avoid biasing the effects of the ε4 allele on pulmonary function by the ε2 allele. After exclusion of carriers of the APOE ε2/ε4 genotype, 4,468 Caucasian LLFS participants were analyzed. They included long-living (LL) individuals (N = 1,302), their offspring (N = 2,259), spouses of LL individuals (N = 158), and spouses of offspring (N = 749).

Lung function outcomes
Quantitative markers of lung function, FEV₁, FVC, and FEV₁/FVC (%), were considered as outcomes. Lung function was measured with a portable spirometer (EasyOne, ndd Medical Technologies, Andover, MA) using American Thoracic Society guidelines[38].

Analysis
In the initial analyses, mean values (age, BMI, FEV₁, FVC, FEV₁/FVC) and proportions (sex, smoking) over three groups of individuals carrying the ε2 allele (ε2/ε2 or ε2/ε3 genotypes), the ε3/ε3 genotype, and the ε4 allele (ε4/ε4 or ε3/ε4 genotypes) were compared using one-way ANOVA with 2 degrees of freedom that does not require correction for multiple comparisons. Associations of the selected APOE genotypes with outcomes were characterized by a two-level mixed effects linear regression model (lme4 package in R) with a random effect to adjust for the LLFS familial structure. Measurement of FEV₁, FVC and FEV₁/FVC were used in their natural scale because no noticeable skewness of their frequency distributions was detected. These statistical models were fitted considering the effect of the ε2 and ε4 alleles as compared to the common ε3/ε3 reference genotype.

Analyses of pooled samples and sex-stratified samples were performed. A test of multiplicative interactions was conducted to quantify differences in the effects between men and women. All statistical tests were adjusted for age, field center, family groups (i.e., probands, their offspring, and spouses) and sex, when applicable.

We investigated whether height, smoking, lipids, and body mass index (BMI) modulated associations of the APOE genotypes with FEV₁, FVC and FEV₁/FVC using models adjusted for each of these factors. BMI was calculated as weight (kg)/height (m)². Standing height was measured using a Handi-stat set square (Perspective Enterprises, Portage, MI) to the nearest 0.1 cm. Weight was measured using an electronic digital scale (SECA 841, Hanover, MD) to the nearest 0.1 kg. Smoking was defined as current smokers. Total cholesterol, LDL- cholesterol (LDL-C), HDL-cholesterol (HDL-C), and triglycerides were measured in serum on a Roche/Modular P Chemistry Analyzer (Roche Diagnostics Corporation) using samples obtained after a 6-hour fast, which could occur during any time of the day. Total cholesterol was measured using a cholesterol oxidase enzymatic method and triglycerides were measured using a glycerol blanking enzymatic method (Roche Diagnostics, Indianapolis, IN). LDL-C was calculated using the Friedewald equation[39].

All analyses were conducted in R.

Results
The 4,468 LLFS participants had a mean age of 70.06 ± 0.23 years and included 2,041 (44.82%) men. 636 subjects reported having lung disease, while 3,832 subjects were without lung disease. The frequencies of the selected three common APOE genotypes among men and women combined, as well as separately are shown in Table 1. The ε3/ε3 genotype was carried by 66.2% of
LLFS participants (men and women combined), followed by \( \varepsilon_4 \) and \( \varepsilon_2 \) being carried by 17.8% and 16.0%, respectively. Carriers of the \( \varepsilon_4 \) allele were the youngest and carriers of the \( \varepsilon_2 \) allele were the oldest. The proportion of men was smallest among the \( \varepsilon_3/\varepsilon_3 \) carriers and largest among the \( \varepsilon_2 \) carriers. Mean values of FEV\(_1\) and FVC were larger among \( \varepsilon_4 \) carriers as

### Table 1. Baseline demographic characteristics and outcomes used in the analyses of the genotyped LLFS participants for men and women combined and separately.

<table>
<thead>
<tr>
<th>Factor</th>
<th>( \varepsilon_2 = \varepsilon_2/\varepsilon_2 ) or ( \varepsilon_2/\varepsilon_3 )</th>
<th>( \varepsilon_3/\varepsilon_3 )</th>
<th>( \varepsilon_4 = \varepsilon_4/\varepsilon_4 ) or ( \varepsilon_3/\varepsilon_4 )</th>
<th>( p)-value (ANOVA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N (%)</td>
<td>715 (16.00)</td>
<td>2959 (66.23)</td>
<td>794 (17.77)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Age, mean (SE), years</td>
<td>71.23 (0.63)</td>
<td>70.58 (0.29)</td>
<td>67.23 (0.49)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Sex, Male, N (%)</td>
<td>345 (48.25)</td>
<td>1292 (43.66)</td>
<td>369 (46.47)</td>
<td>.053</td>
</tr>
<tr>
<td>Smoking, N (%)</td>
<td>302 (42.30)</td>
<td>1238 (41.95)</td>
<td>358 (45.32)</td>
<td>.233</td>
</tr>
<tr>
<td>BMI, mean (SE), kg/m(^2)</td>
<td>27.40 (10.01)</td>
<td>27.14 (9.43)</td>
<td>26.90 (9.75)</td>
<td>.151</td>
</tr>
<tr>
<td>CVD, N (%)</td>
<td>189 (26.33)</td>
<td>789 (26.66)</td>
<td>185 (23.30)</td>
<td>.153</td>
</tr>
<tr>
<td>FEV(_1), mean (SE), [mL]</td>
<td>2398 (33)</td>
<td>2400 (16)</td>
<td>2571 (31)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>FVC, mean (SE), [mL]</td>
<td>3121 (41)</td>
<td>3129 (20)</td>
<td>3366 (38)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>FEV(_1)/FVC, mean (SE) [%]</td>
<td>76.40 (0.28)</td>
<td>76.29 (0.14)</td>
<td>75.82 (0.27)</td>
<td>.261</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N (%)</td>
<td>345 (17.20)</td>
<td>1292 (64.41)</td>
<td>369 (18.39)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Age, mean (SE), years</td>
<td>71.54 (0.88)</td>
<td>71.08 (0.43)</td>
<td>67.91 (0.71)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Smoking, N (%)</td>
<td>166 (48.26)</td>
<td>639 (49.57)</td>
<td>185 (50.41)</td>
<td>.845</td>
</tr>
<tr>
<td>BMI, mean (SE), kg/m(^2)</td>
<td>27.83 (8.33)</td>
<td>27.60 (7.98)</td>
<td>27.21 (7.92)</td>
<td>.124</td>
</tr>
<tr>
<td>CVD, N (%)</td>
<td>100 (28.99)</td>
<td>406 (31.42)</td>
<td>106 (28.73)</td>
<td>.487</td>
</tr>
<tr>
<td>FEV(_1), mean (SE), [mL]</td>
<td>2806 (49)</td>
<td>2841 (25)</td>
<td>3040 (46)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>FVC, mean (SE), [mL]</td>
<td>3664 (58)</td>
<td>3735 (29)</td>
<td>3989 (53)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>FEV(_1)/FVC, mean (SE) [%]</td>
<td>76.00 (0.44)</td>
<td>75.46 (0.23)</td>
<td>75.67 (0.39)</td>
<td>.553</td>
</tr>
<tr>
<td>Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N (%)</td>
<td>370 (15.03)</td>
<td>1667 (67.71)</td>
<td>425 (17.26)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Age, mean (SE), years</td>
<td>70.94 (0.90)</td>
<td>70.18 (0.40)</td>
<td>66.64 (0.68)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Smoking, N (%)</td>
<td>136 (36.76)</td>
<td>599 (36.04)</td>
<td>173 (40.90)</td>
<td>.181</td>
</tr>
<tr>
<td>BMI, mean (SE), kg/m(^2)</td>
<td>27.00 (11.31)</td>
<td>26.79 (10.38)</td>
<td>26.63 (11.10)</td>
<td>.651</td>
</tr>
<tr>
<td>CVD, N (%)</td>
<td>89 (24.05)</td>
<td>383 (22.98)</td>
<td>79 (18.59)</td>
<td>.108</td>
</tr>
<tr>
<td>FEV(_1), mean (SE), [mL]</td>
<td>2018 (35)</td>
<td>2055 (17)</td>
<td>2169 (31)</td>
<td>.003*</td>
</tr>
<tr>
<td>FVC, mean (SE), [mL]</td>
<td>2615 (43)</td>
<td>2655 (20)</td>
<td>2834 (36)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>FEV(_1)/FVC, mean (SE) [%]</td>
<td>76.76 (0.36)</td>
<td>76.95 (0.17)</td>
<td>75.95 (0.38)</td>
<td>.044*</td>
</tr>
</tbody>
</table>

* denotes significant result (\( p\)-value < 0.05).

\(^{1}\) Percentage is within the considered group of the genotyped sample.

N denotes sample size.

Age is accessed at baseline.

Smoking status was defined as a cumulative smoking history of more than 100 cigarettes.

FEV\(_1\) denotes forced expiratory volume in 1 second.

FVC denotes forced vital capacity.

FEV\(_1\)/FVC is the ratio (%) of FEV\(_1\) to FVC.

CVD denotes prevalence of cardiovascular diseases, which included coronary heart disease, heart failure, and stroke.

SE denotes standard error.

Baseline demographic characteristics and phenotypes for lung disease cases and controls without lung disease are given in Table 2.

P-values for the comparison of mean values (age, BMI, FEV\(_1\), FVC, FEV\(_1\)/FVC) and proportions (sex, smoking) amongst three groups of individuals carrying the \( \varepsilon_2 \) allele (\( \varepsilon_2/\varepsilon_2 \) or \( \varepsilon_2/\varepsilon_3 \) genotypes), the \( \varepsilon_3/\varepsilon_3 \) genotype, and the \( \varepsilon_4 \) allele (\( \varepsilon_4/\varepsilon_4 \) or \( \varepsilon_3/\varepsilon_4 \) genotypes) were assessed by one-way ANOVA with 2 degrees of freedom.

https://doi.org/10.1371/journal.pone.0206873.t001
compared to carriers of the ε3/ε3 genotype and ε2 allele when men and women were combined, as well as when stratified by sex. In contrast, the FEV₁/FVC ratio was significantly lower among ε4 female carriers, whereas there was no significant difference in the FEV₁/FVC ratio between APOE allele groups among men and women combined or among men.

Next, we assessed whether an association existed between spirometric values and APOE alleles in the LLFS participants. Table 2 shows that the ε4 allele is significantly associated with a 0.70% reduction in FEV₁/FVC in the sample of men and women combined (p = 0.0214), thereby implying that the ε4 allele carriers have smaller FEV₁/FVC values. Sex-stratified analysis showed that this effect is mostly attributed to women with a 1.24% reduction in the FEV₁/FVC ratio (p = 0.0014). We also verified that the association with reduced FEV₁/FVC in the sample of men and women combined did not reflect a potential bias related to population admixture (S1 Table). Further analyses showed that height, smoking, BMI (S2 Table), and lipids (S3 Table) did not mediate the associations of the APOE alleles with FEV₁, FVC and FEV₁/FVC. There were no significant interactions between the ε4 allele and BMI or smoking (S4 Table). There were also no significant interactions between the ε4 allele and lipids, except for HDL-C in men, in relationship to the FEV₁/FVC ratio (S5 Table). Furthermore, the ε4 allele was significantly associated with FEV₁/FVC in women with or without cardiovascular disease (S6 Table).

We next assessed whether this association persisted when we analyzed the large sub-group of 3,832 control subjects without lung disease (Table 3). This analysis showed a significant association between the ε4 allele and a 0.72% reduction in FEV₁/FVC in the samples of men and women combined (p = 0.0164), as well as a 1.04% reduction in FEV₁/FVC in women alone (p = 0.0078). We also assessed whether the association between the ε4 allele and FEV₁/FVC in women was specifically related to aging (Table 4). This analysis showed that the association between the ε4 allele and FEV₁/FVC was significant in long-living women (age 90.8 ± 6.9 years, mean ± standard deviation), but not in the spouses or children of long-living individuals, or in the spouses of offspring of long-living individuals. Similarly, the association between the ε4 allele and the FEV₁/FVC was significant in LLFS women subjects ≥ 70 years, but not in LLFS women subjects < 70 years.

Lastly, an analysis of interactions showed that sex modified the effect of the ε4 allele on FEV₁, FVC, and FEV₁/FVC in the LLFS participants (Table 5). The interaction between the ε4 allele and sex gained nominal significance (p = 0.045) for FEV₁/FVC, while there was a trend

### Table 2. Associations of the APOE ε2 and ε4 alleles with FEV₁, FVC, and FEV₁/FVC of the genotyped LLFS participants for men and women combined and separately.

| Trait      | Effect allele |   |   |   |
|------------|---------------|----------------|----------------|----------------|----------------|
|            | Men & Women   | Men            | Women          | Men            | Women          |
|            | Beta          | SE            | P-value        | Beta           | SE            | P-value        |
| FEV₁       | ε2            | -11.24        | 22.40          | .616           | 9.42          | 37.63          |
|            | ε4            | 1.98          | 21.70          | .927           | 39.50         | .298           |
|            | FVC           | -34.41        | 23.09          | .211           | -44.68        | 46.19          |
|            | ε4            | 23.09         | 26.08          | .376           | 58.15         | 45.10          |
| FEV₁/FVC   | ε2            | 0.12          | 0.32           | .709           | 0.53          | 0.50           |
|            | ε4            | -0.70         | 0.30           | .021*          | -0.18         | 0.47           |

The ε3/ε3 genotype was considered as the reference.
SE denotes standard error.
Beta denotes the effect size.
* denotes significant result (p-value < 0.05).

https://doi.org/10.1371/journal.pone.0206873.t002
The APOEε4 allele is associated with a reduction of FEV₁/FVC in women.

Table 3. Associations of the APOEε2 and ε4 alleles with FEV₁, FVC and FEV₁/FVC in the sub-group of 3,832 genotyped LLFS participants without lung disease.

<table>
<thead>
<tr>
<th>Trait</th>
<th>Effect allele</th>
<th>Men &amp; Women (Beta ± SE, P-value)</th>
<th>Men (Beta ± SE, P-value)</th>
<th>Women (Beta ± SE, P-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁</td>
<td>ε2</td>
<td>-5.44 ± 22.92 (0.812, 0.812)</td>
<td>12.01 ± 37.73 (0.750, 0.750)</td>
<td>-23.90 ± 26.13 (0.360, 0.360)</td>
</tr>
<tr>
<td></td>
<td>ε4</td>
<td>10.21 ± 22.15 (0.645, 0.645)</td>
<td>44.26 ± 38.25 (0.247, 0.247)</td>
<td>0.11 ± 24.45 (0.996, 0.996)</td>
</tr>
<tr>
<td>FVC</td>
<td>ε2</td>
<td>-29.89 ± 29.36 (0.309, 0.309)</td>
<td>-48.00 ± 48.70 (0.324, 0.324)</td>
<td>33.67 ± 31.42 (0.527, 0.527)</td>
</tr>
<tr>
<td></td>
<td>ε4</td>
<td>33.57 ± 27.47 (0.222, 0.222)</td>
<td>70.34 ± 46.89 (0.134, 0.134)</td>
<td>31.26 ± 31.42 (0.320, 0.320)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>0.16 ± 0.30 (0.016, 0.016)</td>
<td>-0.46 ± 0.46 (0.349, 0.349)</td>
<td>0.11 ± 0.24 (0.996, 0.996)</td>
</tr>
<tr>
<td></td>
<td>ε4</td>
<td>-0.72 ± 0.30 (0.016, 0.016)</td>
<td>0.46 ± 0.46 (0.349, 0.349)</td>
<td>-1.04 ± 0.39 (0.008, 0.008)</td>
</tr>
</tbody>
</table>

The models were fitted with adjustments by age, sex, family groups, and field center. Controls subjects without lung disease are defined in the Methods section. The ε3/ε3 genotype was considered as the reference. * denotes significant result (p-value < 0.05).

https://doi.org/10.1371/journal.pone.0206873.t003

Table 4. Associations of the APOEε2 and ε4 alleles with FEV₁/FVC in different age groups of LLFS participants.

<table>
<thead>
<tr>
<th>Trait</th>
<th>Effect allele</th>
<th>N</th>
<th>Men &amp; Women (Beta ± SE, P-value)</th>
<th>Men (Beta ± SE, P-value)</th>
<th>Women (Beta ± SE, P-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>968</td>
<td>0.41 ± 0.73 (0.575, 0.575)</td>
<td>0.34 ± 1.04 (0.745, 0.745)</td>
<td>0.48 ± 1.02 (0.639, 0.639)</td>
</tr>
<tr>
<td>LL individuals</td>
<td>ε4</td>
<td>907</td>
<td>-1.47 ± 0.87 (0.098, 0.098)</td>
<td>1.21 ± 0.967 (0.967, 0.967)</td>
<td>2.01 ± 0.967 (0.934, 0.934)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>112</td>
<td>1.25 ± 1.76 (0.513, 0.513)</td>
<td>2.75 ± 3.11 (0.388, 0.388)</td>
<td>2.11 ± 2.11 (0.466, 0.466)</td>
</tr>
<tr>
<td>LL spouses</td>
<td>ε4</td>
<td>121</td>
<td>-3.08 ± 1.63 (0.200, 0.200)</td>
<td>-0.30 ± 2.62 (0.909, 0.909)</td>
<td>-4.05 ± 2.01 (0.294, 0.294)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>1696</td>
<td>-0.27 ± 0.36 (0.450, 0.450)</td>
<td>0.31 ± 0.60 (0.612, 0.612)</td>
<td>0.42 ± 0.612 (0.169, 0.169)</td>
</tr>
<tr>
<td>LL offspring</td>
<td>ε4</td>
<td>1739</td>
<td>-0.36 ± 0.34 (0.286, 0.286)</td>
<td>-0.27 ± 0.54 (0.623, 0.623)</td>
<td>-0.55 ± 0.43 (0.206, 0.206)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>533</td>
<td>0.67 ± 0.85 (0.436, 0.436)</td>
<td>1.40 ± 1.27 (0.282, 0.282)</td>
<td>1.17 ± 1.07 (0.694, 0.694)</td>
</tr>
<tr>
<td>Offspring spouses</td>
<td>ε4</td>
<td>630</td>
<td>-0.55 ± 0.62 (0.378, 0.378)</td>
<td>-0.37 ± 1.01 (0.714, 0.714)</td>
<td>-0.87 ± 0.71 (0.225, 0.225)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>1914</td>
<td>-0.21 ± 0.35 (0.554, 0.554)</td>
<td>-0.37 ± 0.37 (0.450, 0.450)</td>
<td>-0.58 ± 0.42 (0.169, 0.169)</td>
</tr>
<tr>
<td>age &lt; 70</td>
<td>ε4</td>
<td>2051</td>
<td>-0.30 ± 0.31 (0.340, 0.340)</td>
<td>-0.24 ± 0.50 (0.629, 0.629)</td>
<td>-0.39 ± 0.39 (0.318, 0.318)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>ε2</td>
<td>1395</td>
<td>0.59 ± 0.58 (0.307, 0.307)</td>
<td>0.89 ± 0.86 (0.305, 0.305)</td>
<td>0.74 ± 0.77 (0.657, 0.657)</td>
</tr>
<tr>
<td>age ≥ 70</td>
<td>ε4</td>
<td>1346</td>
<td>-1.76 ± 0.63 (0.006*, 0.006*)</td>
<td>-0.06 ± 0.95 (0.947, 0.947)</td>
<td>-3.19 ± 0.84 (0.001*, 0.001)*</td>
</tr>
</tbody>
</table>

LL indicates long-living individuals. Mean age and standard deviation (SD) for LL individuals were: 90.4 ± 6.4 years (men and women combined), 89.8 ± 5.7 years (men) and 90.8 ± 6.9 years (women). Mean age and SD for spouses of LL individuals were: 83.1 ± 7.0 years (men and women combined), 85.3 ± 5.5 years (men) and 82.5 ± 7.3 years (women). Mean age and SD for offspring of LL individuals were: 60.5 ± 8.2 years (men and women combined), 60.6 ± 8.2 years (men) and 60.5 ± 8.2 years (women). Mean age and SD for spouses of offspring were: 60.9 ± 8.6 years (men and women combined), 63.1 ± 7.9 years (men) and 58.4 ± 8.7 years (women). LLFS participants were also divided into subjects < or ≥ 70 years of age. * denotes significant result (p-value < 0.05).

https://doi.org/10.1371/journal.pone.0206873.t004

Discuss the human APOE gene is polymorphic and encodes three distinct protein isoforms, APOE2, APOE3, and APOE4, which differ by single amino acid substitutions at amino acids 112 and 158[1, 3]. APOE3 is the most common isoform and contains a cysteine at position 112 and an arginine at position 158[1]. Although these polymorphisms do not involve the receptor- or lipid-binding domains of APOE, they significantly alter its structural and functional properties. APOE2 has markedly
impaired LDLR binding capabilities, which is less than 2% of APOE3 and APOE4\[2\]. The APOE4 isoform has normal LDLR binding, but has altered lipid binding characteristics, with preferential binding to triglyceride-rich VLDL and chylomicron remnants instead of phospholipid-rich high-density lipoproteins\[2\].

The APOE\(\varepsilon4\) allele is the minor allele in modern humans and is a major genetic risk factor for Alzheimer’s disease\[1, 2, 40\]. The APOE\(\varepsilon4\) allele also increases atherosclerosis risk and decreases lifespan\[2, 40\]. APOE\(\varepsilon4\) is the ancestral APOE allele, as it is present in all great apes, while the shift to the APOE\(\varepsilon3\) and APOE\(\varepsilon2\) alleles may have reflected selective pressure from infectious diseases\[2\]. Consistent with this, the human APOE\(\varepsilon4\) allele modifies host responses to infection, such as the human immunodeficiency virus\[2, 40\]. Transgenic knock-in mice expressing the human APOE\(\varepsilon4\) allele have increased morbidity and mortality in experimental sepsis models\[7, 41\]. Similarly, human subjects heterozygous for APOE\(\varepsilon3/\varepsilon4\) have increased innate immune responses to LPS as compared to individuals with the APOE\(\varepsilon3/\varepsilon3\) genotype\[41\]. Furthermore, the APOE\(\varepsilon4\) allele has been associated with increased coagulation system failure in European Americans with severe sepsis\[41\]. Susceptibility to infection by the intracellular bacterial pathogen, Chlamydia pneumoniae, may also be enhanced by the APOE\(\varepsilon4\) allele by a mechanism involving increased attachment to host cells\[42\].

The APOE alleles, however, are not known to modulate pulmonary function in human subjects and have not been linked to pulmonary function in genome-wide association studies\[43–51\]. Although a prior genome-wide association study of LLFS participants identified a linkage peak on chromosome 2 for FEV\(_1\)/FVC, the APOE\(\varepsilon2\), \(\varepsilon3\) and \(\varepsilon4\) alleles were not included in that dataset\[48\]. Here, we show that the mean FEV\(_1\)/FVC ratio was lower among women with the \(\varepsilon4\) allele as compared to women with either the \(\varepsilon3/\varepsilon3\) genotype or the \(\varepsilon2\) allele. In addition, carriage of the APOE\(\varepsilon4\) allele in the LLFS participants was associated with the FEV\(_1\)/FVC ratio, which implied a smaller value, as compared to carriers of the APOE\(\varepsilon3\) allele. Although a reduction in the FEV\(_1\)/FVC ratio could reflect the presence of airflow obstruction, both the FVC and FEV\(_1\) were increased in carriers of the APOE\(\varepsilon4\) allele as compared to carriers of the \(\varepsilon3/\varepsilon3\) genotype or the \(\varepsilon2\) allele. This suggests that the reduction in the FEV\(_1\)/FVC ratio in carriers of the APOE\(\varepsilon4\) allele might instead represent modified lung physiology reflected by a proportionally larger FVC than FEV\(_1\). For example, dysanaptic or unequal lung growth has been reported to occur in teenagers, where growth of the airways, as reflected by the FEV\(_1\), relative to lung volumes, as reflected by the FVC, occurs more slowly in girls than boys\[52, 53\]. Furthermore, dysanaptic lung growth has been reported in the setting of chronic hypoxia and

### Table 5. Associations of the APOE\(\varepsilon2\) and \(\varepsilon4\) alleles with FEV\(_1\), FVC, and FEV\(_1\)/FVC and their multiplicative interactions with sex in the genotyped LLFS participants.

<table>
<thead>
<tr>
<th>Trait</th>
<th>apoE</th>
<th>apoE</th>
<th>apoE×sex</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Beta</td>
<td>SE</td>
<td>P-value</td>
</tr>
<tr>
<td>FEV(_1)</td>
<td>(\varepsilon2)</td>
<td>-29.44</td>
<td>30.83</td>
</tr>
<tr>
<td></td>
<td>(\varepsilon4)</td>
<td>-33.60</td>
<td>29.03</td>
</tr>
<tr>
<td>FVC</td>
<td>(\varepsilon2)</td>
<td>-28.98</td>
<td>36.97</td>
</tr>
<tr>
<td></td>
<td>(\varepsilon4)</td>
<td>-8.92</td>
<td>34.56</td>
</tr>
<tr>
<td>FEV(_1)/FVC</td>
<td>(\varepsilon2)</td>
<td>-0.20</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>(\varepsilon4)</td>
<td>-1.22</td>
<td>0.40</td>
</tr>
</tbody>
</table>

The models with interactions considered men as a reference category. The \(\varepsilon3/\varepsilon3\) genotype was considered as the reference. * denotes significant result (p-value < 0.05).

https://doi.org/10.1371/journal.pone.0206873.t005
post-infectious bronchiolitis obliterans, which results in a decrease in the FEV\(_1\)/FVC ratio\[53,54\]. Since the reduction in FEV\(_1\)/FVC in carriers of the APOE \(\varepsilon4\) allele was specific for individuals over 70 years of age, we believe that it is unlikely that dysanaptic lung development is the explanation for this finding. The FEV\(_1\)/FVC ratio is well-known to decrease with advancing age, which suggests that the reduction in FEV\(_1\)/FVC among carriers of the APOE \(\varepsilon4\) allele might instead reflect modified lung aging in older individuals\[55–58\]. This finding will need to be confirmed by future studies that assess whether the reduction in FEV\(_1\)/FVC among carriers of the APOE \(\varepsilon4\) allele is limited to older individuals, in which case it would not be generalizable to younger study populations. Similarly, future studies would be required to assess whether this finding is limited to individuals with exceptional familial longevity or is also generalizable to populations with normal longevity.

The association between the APOE \(\varepsilon4\) allele and a lower FEV\(_1\)/FVC ratio persisted when the sub-group of LLFS women without lung disease was analyzed. To the best of our knowledge, this demonstrates for the first time that an association exists between the polymorphic APOE alleles and lung function in human subjects. Although the effect size on FEV\(_1\)/FVC was modest, the effect of an individual allele on a complex genetic trait is often relatively small. In addition, since the effect was present in individuals without lung disease, a large magnitude of change was not expected. Furthermore, our results suggest that a link might exist between the APOE \(\varepsilon4\) allele, female sex, and a lower FEV\(_1\)/FVC ratio in older individuals. This may provide a new insight regarding how the polymorphic APOE alleles might influence human lung physiology in a gender-specific fashion during aging.

These data also raise the hypothesis that the APOE alleles might modify disease pathogenesis or severity in obstructive airway diseases, such as asthma, COPD, or asthma-COPD overlap syndrome. In a prior study we showed that serum apoE levels were similar in normals and asthmatics and were not correlated with FEV\(_1\), however, subjects were not stratified by APOE genotype\[59\]. A limitation of this current study is that we were not able to assess if the APOE alleles modified pulmonary function in subjects with lung disease. We did not include a sub-group analysis of cases with lung disease for several reasons. First, lung disease was self-reported by participants at baseline and during follow up, but the diagnosis of lung disease was not confirmed. Second, because the types of lung disease were heterogeneous regarding diagnoses, severity, and duration, and the number of cases with lung disease was small, an analysis of this sub-group would likely not have sufficient power to identify an association between the APOE alleles and pulmonary function. Third, a subset of the cases with lung disease were utilizing lung disease medications, such as bronchodilators and corticosteroids, which could have modified their pulmonary function results. Therefore, additional studies will be required to assess whether the APOE \(\varepsilon4\) allele is associated with modified pulmonary function in individuals with lung disease. Another limitation of this study is that LLFS participants were selected based upon the trait of exceptional familial longevity. Therefore, additional studies will be needed to assess whether the association between the FEV\(_1\)/FVC ratio and the APOE \(\varepsilon4\) allele in older women is also present in individuals who do not have long-living families.

The mechanisms by which the APOE \(\varepsilon4\) allele might be associated with a relative reduction in airflow in women without lung disease are not known. Prior murine studies have identified that the APOE/LDLR pathway is present in the lung, with the LDLR being expressed by ciliated airway epithelial cells where it could potentially modify airway physiology\[10\]. Furthermore, studies using Apoe- and Ldlr-deficient mice have shown that these genes participate in developmental alveologenesis in a sexually dimorphic fashion\[13,14\]. In addition, Apoe- and Ldlr-deficient mice that have been sensitized and challenged with house dust mite have abnormal airway function with increased mucus cell metaplasia and airway hyperreactivity to methacholine\[10\]. The APOE \(\varepsilon4\) allele has also been associated with enhanced risk and accelerated decline in cognitive...
function secondary to Alzheimer’s disease in women as compared to men[60]. The APOE ε4 allele was also highly significantly associated with shorter lifespan in women as compared to men in the LLFS study and the Framingham Heart Study[61]. Furthermore, prior studies have supported the concept of sexual dimorphism of the ε4 allele in relationship to APOE-related mortality and heart disease[62–65]. Gender-specific effects of the APOE gene might be attributed to differential hormonal and insulin regulation in each sex[62]. Collectively, these findings provide additional evidence to support a gender-specific effect of the ε4 allele on the FEV₁/FVC ratio.

Based upon differences in height and lung volume, absolute values for FEV₁ and FVC are known to be lower in adult women than adult men[66, 67]. Consistent with this, we found that the absolute values for FEV₁ and FVC were significantly lower in women than men, irrespective of whether they carried the APOE ε2, ε3, or ε4 allele, as evidenced by well-separated 95% confidence intervals for FEV₁ and FVC measured in men and women as +/- 1.96 SE (Table 1). In contrast, the FEV₁/FVC ratio was not different between men and women when the sample population was not stratified by age. Therefore, we believe that our finding of a significant reduction in the FEV₁/FVC ratio limited to the subset of older women greater or equal to 70 years of age who carried the APOE ε4 allele did not merely reflect a compounding effect of genotype in individuals who already had lower values by virtue of sex.

In conclusion, we have identified that carriage of the APOE ε4 allele was associated with a decrease in the FEV₁/FVC ratio as compared to carriers of the APOE ε3 allele among women without lung disease who participated in the LLFS. This suggests that carriage of the APOE ε4 allele may be linked to modified lung physiology in a sexually dimorphic fashion in older individuals.

Supporting information

S1 Table. The role of potential population structure in the associations of the APOE ε2 and ε4 alleles with FEV₁, FVC and FEV₁/FVC in the genotyped LLFS participants.
(DOCX)

S2 Table. The role of height, smoking, and BMI in the associations of the APOE ε2 and ε4 alleles with FEV₁, FVC and FEV₁/FVC in the genotyped LLFS participants.
(DOCX)

S3 Table. The role of lipids in the associations of the APOE ε2 and ε4 alleles with FEV₁, FVC and FEV₁/FVC in the genotyped LLFS participants.
(DOCX)

S4 Table. Interactions of the APOE ε2 and ε4 alleles with smoking and BMI in the relationship to FEV₁/FVC.
(DOCX)

S5 Table. Interactions of the APOE ε2 and ε4 alleles with lipids in the relationship to FEV₁/FVC.
(DOCX)

S6 Table. Associations of the APOE ε2 and ε4 alleles with FEV₁/FVC in individuals with and without cardiovascular disease (CVD).
(DOCX)

Author Contributions

Conceptualization: Alexander M. Kulminski, Amisha V. Barochia, Nalini Raghavachari, Stewart J. Levine.
Data curation: Alexander M. Kulminski, Yury Loika, Konstantin G. Wojczynski, Bharat Thyagarajan.

Formal analysis: Alexander M. Kulminski, Yury Loika.

Funding acquisition: Kaare Christensen, Anatoliy I. Yashin.

Methodology: Alexander M. Kulminski, Amisha V. Barochia, Nalini Raghavachari, Mary K. Wojczynski, Bharat Thyagarajan, Badri N. Vardarajan, Stewart J. Levine.

Writing – original draft: Alexander M. Kulminski, Amisha V. Barochia, Stewart J. Levine.

Writing – review & editing: Alexander M. Kulminski, Amisha V. Barochia, Yury Loika, Nalini Raghavachari, Konstantin G. Arbeev, Mary K. Wojczynski, Bharat Thyagarajan, Badri N. Vardarajan, Kaare Christensen, Anatoliy I. Yashin, Stewart J. Levine.

References


